脉冲生物科学 PLSE 深 沪
已收盘 04-02 16:00:00 美东时间
23.00
-0.030
-0.13%
华盛通- 最 高23.66
- 今 开22.29
- 成交量 14.36万股
- 最 低 22.16
- 昨 收 23.03
- 总市值 15.64亿
- 52周最高 26.30
- 市盈率 静 --
- 换手率 0.21%
- 52周最低 12.56
- 委 比 77.98%
- 总股本 6798.91万
- 历史最高 45.82
- 量 比 0.69
- 振 幅 6.51%
- 历史最低 1.18
- 每 手 1
- 风险率 2.54%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pulse Biosciences Begins First Human Study Of New Device To Treat Small Thyroid Cancer Tumors
Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced first
03-12 19:06
Pulse Biosciences Q4 Earnings Report: What Investors Need to Know
The Q4 earnings report for Pulse Biosciences (NASDAQ:PLSE) was released on Thur...
02-20 05:08
Earnings Scheduled For February 19, 2026
Companies Reporting Before The Bell • Deere (NYSE:DE) is expected to report qua...
02-19 19:11
A Glimpse of Pulse Biosciences's Earnings Potential
Pulse Biosciences (NASDAQ:PLSE) will release its quarterly earnings report on T...
02-19 03:01
美股牛股 | 华仕伯大涨超34%！有望获Transocean以58亿美元收购；Playboy涨超33%
华仕伯大涨超34%！有望获Transocean以58亿美元收购，打造领先海上钻井巨头；Playboy涨超33%，拟1.22亿美元出售50%中国业务；脉冲生物科学涨超16%>>
02-10 15:18
What's Going With Pulse Biosciences Stock On Monday?
Pulse Biosciences stock rises after new study data showed strong early results for its heart treatment device, helping shares outperform a weak broader market.
02-09 22:18
美股周涨跌榜 | 光通信龙头Lumentum业绩炸裂！周内飙涨逾40%；创新药公司MANE上市股价即翻倍
光通信龙头Lumentum业绩炸裂！周内股价飙涨逾40%；创新药公司MANE上市即翻倍，聚焦脱发口服药物；德州仪器75亿美元收编芯科实验室>>
02-07 11:39
Reported Earlier, Pulse Biosciences Highlights nPulse Cardiac Catheter Ablation Study Achieving Durable AF Treatment Outcomes With Average Procedure Time Of 65 Minutes And Low SAE Rate
Procedural success was achieved in 100% of evaluable patients at 6 months and 96% in 12 months
02-06 16:37
Pulse Biosciences gains FDA IDE for NANOPULSE-AF trial
An announcement from Pulse Biosciences ( ($PLSE) ) is now available. On Decembe...
2025-12-18 22:28
Pulse Biosciences Teams Up With MD Anderson To Test New Thyroid Cancer Treatment In FDA-Approved Study
Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or
2025-12-09 20:10
